Your browser is no longer supported. Please, upgrade your browser.
Settings
SNY Sanofi daily Stock Chart
SNY [NASD]
Sanofi
Index- P/E10.03 EPS (ttm)5.23 Insider Own16.40% Shs Outstand2.50B Perf Week1.08%
Market Cap130.19B Forward P/E13.96 EPS next Y3.76 Insider Trans0.00% Shs Float2.25B Perf Month1.39%
Income13.16B PEG1.10 EPS next Q1.09 Inst Own7.30% Short Float0.15% Perf Quarter0.23%
Sales44.53B P/S2.92 EPS this Y-32.80% Inst Trans-4.48% Short Ratio3.35 Perf Half Y37.93%
Book/sh29.87 P/B1.76 EPS next Y9.53% ROA- Target Price58.38 Perf Year16.74%
Cash/sh7.60 P/C6.90 EPS next 5Y9.10% ROE- 52W Range37.62 - 55.00 Perf YTD4.46%
Dividend1.70 P/FCF- EPS past 5Y-6.40% ROI3.50% 52W High-4.65% Beta0.49
Dividend %3.24% Quick Ratio1.40 Sales past 5Y3.30% Gross Margin67.80% 52W Low39.39% ATR0.94
Employees100409 Current Ratio1.90 Sales Q/Q0.30% Oper. Margin- RSI (14)55.43 Volatility0.97% 1.41%
OptionableYes Debt/Eq0.39 EPS Q/Q781.40% Profit Margin- Rel Volume0.68 Prev Close52.07
ShortableYes LT Debt/Eq0.34 EarningsJul 29 BMO Payout- Avg Volume997.55K Price52.44
Recom1.40 SMA202.72% SMA501.64% SMA2006.52% Volume680,288 Change0.71%
Mar-17-20Upgrade Barclays Underweight → Equal Weight
Mar-11-20Upgrade Goldman Neutral → Buy
Feb-11-20Initiated SVB Leerink Mkt Perform
Jan-06-20Upgrade JP Morgan Neutral → Overweight
Sep-23-19Upgrade Guggenheim Neutral → Buy
Sep-20-19Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-03-19Initiated Bernstein Outperform
Aug-14-19Upgrade UBS Neutral → Buy
Dec-11-18Upgrade Jefferies Hold → Buy
Nov-01-18Upgrade Barclays Underweight → Equal Weight
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Neutral → Buy
Aug-10-18Upgrade Citigroup Neutral → Buy
Mar-23-18Upgrade Liberum Hold → Buy
Jan-23-18Downgrade Barclays Equal Weight → Underweight
Dec-06-17Downgrade BofA/Merrill Buy → Neutral
Dec-01-17Downgrade Morgan Stanley Overweight → Underweight
Nov-15-17Upgrade Barclays Underweight → Equal Weight
Aug-30-17Upgrade HSBC Securities Reduce → Hold
May-11-17Downgrade Berenberg Buy → Hold
Sep-18-20 04:44PM  
04:02PM  
03:57PM  
12:11PM  
11:40AM  
11:12AM  
09:12AM  
07:12AM  
05:27AM  
03:05AM  
01:00AM  
Sep-17-20 05:48PM  
05:02PM  
Sep-16-20 02:04PM  
10:33AM  
Sep-15-20 03:00PM  
01:56PM  
01:11PM  
Sep-14-20 09:51AM  
01:00AM  
Sep-12-20 08:40AM  
Sep-11-20 12:00PM  
11:30AM  
09:16AM  
Sep-10-20 01:00AM  
Sep-09-20 07:00AM  
Sep-08-20 04:39PM  
04:29PM  
01:58PM  
10:33AM  
07:48AM  
06:30AM  
06:30AM  
04:59AM  
03:32AM  
01:00AM  
Sep-06-20 09:00AM  
Sep-05-20 05:10AM  
04:50AM  
Sep-04-20 09:25AM  
06:59AM  
Sep-03-20 05:01PM  
04:15PM  
04:12PM  
03:31PM  
03:14PM  
03:12PM  
10:15AM  
09:47AM  
09:41AM  
09:37AM  
07:59AM  
Sep-01-20 07:18PM  
04:10PM  
10:04AM  
09:09AM  
08:39AM  
08:32AM  
06:50AM  
04:03AM  
03:02AM  
01:52AM  
Aug-26-20 07:52AM  
03:54AM  
Aug-25-20 01:52PM  
Aug-24-20 11:35AM  
08:30AM  
Aug-21-20 10:12AM  
Aug-19-20 04:48PM  
11:22AM  
Aug-18-20 10:42AM  
06:19AM  
Aug-17-20 06:53PM  
04:57PM  
04:25PM  
04:18PM  
04:01PM  
02:19PM  
02:16PM  
12:58PM  
11:34AM  
10:02AM  
08:55AM  
08:46AM  
08:37AM  
08:33AM  
07:58AM  
07:00AM  
06:59AM  
05:45AM  
05:05AM  
04:25AM  
04:14AM  
01:56AM  
01:12AM  
01:00AM  
Aug-16-20 07:54PM  
10:19AM  
Aug-14-20 02:43PM  
Aug-13-20 05:33PM  
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; and Kymera Therapeutics. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJul 28Buy16.0081,2501,300,000520,125Jul 29 06:06 AM
Sanofi10% OwnerJun 09Sale597.48120,23471,837,410279,766Jun 11 06:45 PM
Sanofi10% OwnerMay 29Sale509.852,399,5521,223,411,587400,000May 29 04:16 PM
Sanofi10% OwnerMay 29Sale509.8520,421,89910,412,105,2050May 29 04:16 PM
Sanofi10% OwnerMar 09Sale489.65128,91463,123,15320,421,899Mar 11 05:00 PM